This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for PT Indofarma Tbk's Median PS Value or its related term are showing as below:
ISX:INAF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7 Med: 1.14 Max: 3.37
Current: 0.98
During the past 13 years, the highest Price to Median PS Value of PT Indofarma Tbk was 3.37. The lowest was 0.70. And the median was 1.14.
ISX:INAF's Price-to-Median-PS-Value is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.83
vs ISX:INAF: 0.98
PT Indofarma Tbk (ISX:INAF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
PT Indofarma Tbk's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
126.00
/
128.99
=
0.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Indofarma Tbk Median PS Value Related Terms
PT Indofarma Tbk Median PS Value Historical Data
* Premium members only.
The historical data trend for PT Indofarma Tbk's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:INAF vs ZTS, VTRS, NBIX: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Indofarma Tbk Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where PT Indofarma Tbk's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.6379.
PT Indofarma Tbk's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp48.899.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Indofarma Tbk (ISX:INAF) has a Median PS Value of Rp128.99 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on PT Indofarma Tbk and its competitors. This is 11215% above median its historical median of 1.14. Over the past decade, PT Indofarma Tbk's Median PS Value has ranged from 0.70 to 3.37.
Is PT Indofarma Tbk's Median PS Value too high?
PT Indofarma Tbk's current Median PS Value of Rp128.99 is 11215% above median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 3.37. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Median PS Value compare to ZTS and VTRS?
PT Indofarma Tbk's Median PS Value of Rp128.99 can be compared against companies in the Drug Manufacturers industry. The industry median Median PS Value is 0.83. Historically, PT Indofarma Tbk's own Median PS Value has ranged from 0.70 to 3.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.83, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on PT Indofarma Tbk and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Indofarma Tbk's current Median PS Value is Rp128.99, which is 11215% above median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Median PS Value of Rp128.99. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Median PS Value is Rp128.99, which is 11215% above median its 10-year median of 1.14. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Median PS Value is Rp128.99 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued.
The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.
Key valuation signals for ISX:INAF:
Median PS Value: Rp128.99 (11215% above median its 10-year median of 1.14)
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score
Get the complete analysis for ISX:INAF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:INAF has been successfully added to your 
